secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001517022-26-000019
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Q4 net product revenue $54.3M, full-year 2025 up 49% YoY; Vafseo launch gains traction
--------------------------------------------------------------------------------

- Q4 total revenue $57.6M (FY2025 $236.2M); net loss narrowed to $12.2M Q4 and $5.3M full year.
- Vafseo net product revenue $6.2M Q4, $45.8M full year 2025; 800 prescribers, 91% adherence with observed dosing.
- Auryxia net rev $181.5M FY2025; generic competition expected to reduce 2026 Auryxia revenue.
- Cash $184.8M vs $51.9M year-end 2024; sufficient for at least two years.
- Pipeline: praliciguat Phase 2 FSGS started; AKB-097 basket study in 2H 2026; AKB-9090 Phase 1 in 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000019/0001517022-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000019/akba-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001517022-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer